Impact of variation in cancer registration practice on observed international cancer survival differences between International Cancer Benchmarking Partnership (ICBP) jurisdictions.


Journal

Cancer epidemiology
ISSN: 1877-783X
Titre abrégé: Cancer Epidemiol
Pays: Netherlands
ID NLM: 101508793

Informations de publication

Date de publication:
02 2019
Historique:
received: 20 07 2018
revised: 08 10 2018
accepted: 10 10 2018
pubmed: 15 1 2019
medline: 19 12 2019
entrez: 15 1 2019
Statut: ppublish

Résumé

International cancer survival comparisons use cancer registration data to report cancer survival, which informs the development of cancer policy and practice. Studies like the International Cancer Benchmarking Partnership (ICBP) have a duty to understand how registration differences impact on survival prior to drawing conclusions. Key informants reported differences in registration practice for capturing incidence date, death certificate case handling and registration of multiple primary tumours. Sensitivity analyses estimated their impact on one-year survival using baseline and supplementary cancer registration data from England and Sweden. Variations in registration practice accounted for up to a 7.3 percentage point difference between unadjusted (estimates from previous ICBP survival data) and adjusted (estimates recalculated accounting for registration differences) one-year survival, depending on tumour site and jurisdiction. One-year survival estimates for four jurisdictions were affected by adjustment: New South Wales, Norway, Ontario, Sweden. Sweden and Ontario's survival reduced after adjustment, yet they remained the jurisdictions with the highest survival for breast and ovarian cancer respectively. Sweden had the highest unadjusted lung cancer survival of 43.6% which was adjusted to 39.0% leaving Victoria and Manitoba with the highest estimate at 42.7%. For colorectal cancer, Victoria's highest survival of 85.1% remained unchanged after adjustment. Population-based cancer survival comparisons can be subject to registration biases that may impact the reported 'survival gap' between populations. Efforts should be made to apply consistent registration practices internationally. In the meantime, survival comparison studies should provide acknowledgement of or adjustment for the registration biases that may affect their conclusions.

Sections du résumé

BACKGROUND
International cancer survival comparisons use cancer registration data to report cancer survival, which informs the development of cancer policy and practice. Studies like the International Cancer Benchmarking Partnership (ICBP) have a duty to understand how registration differences impact on survival prior to drawing conclusions.
METHODS
Key informants reported differences in registration practice for capturing incidence date, death certificate case handling and registration of multiple primary tumours. Sensitivity analyses estimated their impact on one-year survival using baseline and supplementary cancer registration data from England and Sweden.
RESULTS
Variations in registration practice accounted for up to a 7.3 percentage point difference between unadjusted (estimates from previous ICBP survival data) and adjusted (estimates recalculated accounting for registration differences) one-year survival, depending on tumour site and jurisdiction. One-year survival estimates for four jurisdictions were affected by adjustment: New South Wales, Norway, Ontario, Sweden. Sweden and Ontario's survival reduced after adjustment, yet they remained the jurisdictions with the highest survival for breast and ovarian cancer respectively. Sweden had the highest unadjusted lung cancer survival of 43.6% which was adjusted to 39.0% leaving Victoria and Manitoba with the highest estimate at 42.7%. For colorectal cancer, Victoria's highest survival of 85.1% remained unchanged after adjustment.
CONCLUSION
Population-based cancer survival comparisons can be subject to registration biases that may impact the reported 'survival gap' between populations. Efforts should be made to apply consistent registration practices internationally. In the meantime, survival comparison studies should provide acknowledgement of or adjustment for the registration biases that may affect their conclusions.

Identifiants

pubmed: 30639877
pii: S1877-7821(18)30293-5
doi: 10.1016/j.canep.2018.10.019
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

184-192

Informations de copyright

Copyright © 2018. Published by Elsevier Ltd.

Auteurs

Michael Eden (M)

National Cancer Registry and Analysis Service (NCRAS), England, UK. Electronic address: Michael.Eden@phe.gov.uk.

Samantha Harrison (S)

Policy and Information, Cancer Research UK, England, UK. Electronic address: Samantha.harrison@cancer.org.uk.

Michelle Griffin (M)

National Disease Registration, Public Health England, England, UK. Electronic address: michelle.griffin@phe.gov.uk.

Mats Lambe (M)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Sweden. Electronic address: mats.lambe@ki.se.

David Pettersson (D)

National Board of Health and Welfare, Stockholm, Sweden. Electronic address: david.pettersson@socialstyrelsen.se.

Anna Gavin (A)

N. Ireland Cancer Registry, Queen's University Belfast, Northern Ireland, UK. Electronic address: a.gavin@qub.ac.uk.

David H Brewster (DH)

Scottish Cancer Registry, NHS National Services Scotland, Scotland, UK. Electronic address: David.H.Brewster@ed.ac.uk.

Yulan Lin (Y)

European Palliative Care Research Centre (PRC), Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Norway. Electronic address: yulan.lin@ntnu.no.

Tom B Johannesen (TB)

Cancer Registry of Norway, Oslo, Norway. Electronic address: tom.borge.johannesen@kreftregisteret.no.

Roger L Milne (RL)

Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, Melbourne, Australia. Electronic address: roger.milne@cancervic.org.au.

Helen Farrugia (H)

Victorian Cancer Registry, Cancer Council Victoria, Melbourne, Australia. Electronic address: helen.farrugia@cancervic.org.au.

Diane Nishri (D)

Prevention and Cancer Control, Cancer Care Ontario, Ontario, Canada. Electronic address: Diane.Nishri@cancercare.on.ca.

Mary-Jane King (MJ)

Ontario Cancer Registry, Cancer Care Ontario, Ontario, Canada. Electronic address: MaryJane.King@cancercare.on.ca.

Dyfed W Huws (DW)

Welsh Cancer Intelligence and Surveillance Unit, Public Health Wales, Wales, UK. Electronic address: dyfed.huws@wales.nhs.uk.

Janet Warlow (J)

Welsh Cancer Intelligence and Surveillance Unit, Public Health Wales, Wales, UK. Electronic address: janet.warlow@wales.nhs.uk.

Donna Turner (D)

Epidemiology and Cancer Registry, CancerCare Manitoba, Manitoba, Canada. Electronic address: Donna.Turner@cancercare.mb.ca.

Craig C Earle (CC)

Institute for Clinical Evaluative Sciences, Ontario Institute for Cancer Research, Ontario, Canada. Electronic address: Craig.Earle@partnershipagainstcancer.ca.

Michael Peake (M)

Respiratory Medicine, University of Leicester and National Cancer Registration and Analysis Service (NCRAS), England, UK. Electronic address: mick.peake@uhl-tr.nhs.uk.

Jem Rashbass (J)

National Disease Registration, Public Health England, England, UK. Electronic address: Jem.Rashbass@phe.gov.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH